SCHEMBL6018064

SCHEMBL6018064

Cn1c(-c2c(F)cccc2F)nc(C(=O)NCc2ccc(C(F)(F)F)c(F)c2)c(O)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNE1 P15382 1/20 0.44
CCR1 P32246 1/20 0.44
KCNQ1 P51787 1/20 0.44
P2RX7 Q99572 3/20 0.43
PTGER4 P35408 1/20 0.43
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
LIPG Q9Y5X9 1/20 0.41
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
SCD O00767 1/20 0.38
AADAT Q8N5Z0 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TACR1 P25103 1/20 0.37
CD38 P28907 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017839 0.89 SCD (0.46) KCNE1CCR1KCNQ1LIPGADORA2A
SCHEMBL6017870 0.88 KCNE1 (0.47) KCNE1CCR1KCNQ1PTGER4PPARA
SCHEMBL6017734 0.87 TACR1 (0.50) KCNE1CCR1KCNQ1SMN1; SMN2TACR1
SCHEMBL6017737 0.87 KCNE1 (0.44) KCNE1CCR1KCNQ1LIPGADORA2A
SCHEMBL6017708 0.85 KCNE1 (0.48) KCNE1CCR1KCNQ1SMN1; SMN2AADAT
SCHEMBL6017627 0.85 KCNE1 (0.54) KCNE1CCR1KCNQ1LIPGSMN1; SMN2
SCHEMBL6018223 0.85 CNR1 (0.48) KCNE1CCR1KCNQ1MEN1KMT2A
SCHEMBL6017784 0.84 P2RX7 (0.45) KCNE1CCR1KCNQ1P2RX7PPARG
SCHEMBL6017779 0.84 KCNE1 (0.42) KCNE1CCR1KCNQ1LIPGADORA2A
SCHEMBL6018572 0.84 KMT2A (0.49) KCNE1CCR1KCNQ1LIPGSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US claimed
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS KCNE1 3647/4885CCR1 1187/4885KCNQ1 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.